Table 2.
Region or country-wise ILD complication and anti-Jo1 antibody positivity rates among patients with ASyS
| Asian cohort | European cohort | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Our cohort | Sodsri et al. [16] |
Zhang et al. [17] |
Wang et al. [18] |
Hum et al. [19] |
Preger et al. [20] |
Martins et al. [21] |
Asia Total |
Europe Total |
|
| Year | 2025 | 2023 | 2023 | 2022 | 2024 | 2023 | 2022 | ||
| Country or region | Japan | Thailand | China | China | Europe | Sweden | Portugal | ||
| Race | Asian 100% | ND | Asian 100% | Asian 100% | ND | White 98% | ND | ||
| Sample size, n | 48 | 82 | 119 | 88 | 649 | 50 | 70 | 337 | 769 |
|
ASyS with ILD, n (%) |
47 (98) |
64 (78) |
111 (93) |
79 (90) |
441 (68) |
39 (80) |
53 (76) |
301 (89) |
533 (69) |
| ASyS with anti-Jo1 antibody, n (%) |
17 (35) |
22 (27) |
59 (50) |
42 (48) |
541 (83) |
45 (90) |
43 (61) |
140 (42) |
629 (82) |
ILD Interstitial lung disease, ASyS Antisynthetase syndrome, ND no data